[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vivani Medical Inc (VANI)

Vivani Medical Inc (VANI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 127,186
  • Shares Outstanding, K 90,203
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,610 K
  • EBIT $ -27 M
  • EBITDA $ -27 M
  • 60-Month Beta 2.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.32

Options Overview Details

View History
  • Implied Volatility 253.34% (-369.06%)
  • Historical Volatility 55.36%
  • IV Percentile 49%
  • IV Rank 25.71%
  • IV High 692.63% on 12/11/25
  • IV Low 101.35% on 04/14/26
  • Expected Move (DTE 27) 0.0000 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 27
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 2,989
  • Open Int (30-Day) 2,969
  • Expected Range 1.3800 to 1.3800

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.07
  • Number of Estimates 1
  • High Estimate $-0.07
  • Low Estimate $-0.07
  • Prior Year $-0.11
  • Growth Rate Est. (year over year) +36.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2403 +11.26%
on 07/28/26
1.5300 -9.80%
on 08/19/26
-0.0500 (-3.50%)
since 07/21/26
3-Month
1.1000 +25.45%
on 06/15/26
1.6607 -16.90%
on 07/09/26
+0.2200 (+18.97%)
since 05/21/26
52-Week
0.9228 +49.54%
on 03/30/26
1.9200 -28.12%
on 10/21/25
+0.1700 (+14.05%)
since 08/21/25

Most Recent Stories

More News
Vivani Medical: Q2 Earnings Snapshot

Vivani Medical: Q2 Earnings Snapshot

VANI : 1.3800 (-2.13%)
Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update

All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data...

VANI : 1.3800 (-2.13%)
Vivani Medical Announces Successful Dosing of All Participants in SLIM-1, a Phase 1 Trial Evaluating NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants. SLIM-1 ™ trial is a Phase 1, randomized, controlled clinical trial...

VANI : 1.3800 (-2.13%)
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026

ALAMEDA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, biopharmaceutical company developing novel, miniature, GLP-1...

VANI : 1.3800 (-2.13%)
Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

ALAMEDA, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), an innovative, biopharmaceutical company developing novel, ultra long-acting...

VANI : 1.3800 (-2.13%)
Vivani Announces Entry into Merger Agreement Between Wholly Owned Subsidiary Cortigent, Inc. and Nasdaq-listed ClearOne, Inc.

Vivani proposes to merge Cortigent, Inc. with a wholly owned subsidiary of ClearOne, Inc. (Nasdaq: CLRO), and change the listed company’s name and ticker to Cortigent Holdings, Inc. (d/b/a Cortigent)...

CLRO : 5.34 (-4.30%)
VANI : 1.3800 (-2.13%)
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker

ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...

FDMT : 15.83 (-1.68%)
VANI : 1.3800 (-2.13%)
Vivani Medical Receives Regulatory Approval for the Initiation of SLIM-1, a Phase 1 Clinical Trial of NPM-139 Semaglutide Implant in Obesity and Chronic Weight Management

ALAMEDA, Calif., June 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting...

VANI : 1.3800 (-2.13%)
Vivani Medical CEO Adam Mendelsohn to Present at the 2026 BIO International Convention

ALAMEDA, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra...

VANI : 1.3800 (-2.13%)
Vivani Medical CEO Adam Mendelsohn to Present at the Jefferies Global Healthcare Conference on June 4, 2026

ALAMEDA, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. ( NASDAQ: VANI ) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra...

VANI : 1.3800 (-2.13%)

Business Summary

Vivani Medical Inc. is the combination of Nano Precision Medical, Inc. and Second Sight Medical Products, Inc. The Company leverages proprietary technologies to develop and commercialize drug and device implants that treat patients with chronic diseases. Vivani Medical Inc., formerly known as Second...

See More

Key Turning Points

3rd Resistance Point 1.5000
2nd Resistance Point 1.4700
1st Resistance Point 1.4250
Last Price 1.3800
1st Support Level 1.3500
2nd Support Level 1.3200
3rd Support Level 1.2750

See More

52-Week High 1.9200
Fibonacci 61.8% 1.5391
Fibonacci 50% 1.4214
Last Price 1.3800
Fibonacci 38.2% 1.3037
52-Week Low 0.9228

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.